Actavia Life Sciences, Inc.

Market Cap $3.09M
Debt $42.29K
Cash $87.36K
EV $3.04M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$406.65K
EBIT	-$345.27K
ROA	-710%
Equity	-$2.18M
Growth Stability	1
PE	-7.59
PB	-1.42
Price/Cash	0.03
Debt/Equity	-0.02
Equity CAGR	-1%
Earnings Growth YoY	-98%
Earnings Growth QoQ	-35%

Equity CAGR 5Y	-0%
Market Cap	$3.09M
Assets	$48.61K
Total Debt	$42.29K
Cash	$87.36K
Shares Outstanding	771.81M
EV	3.04M
Shares Growth 3y	73%
Equity Growth QoQ	4%
Equity Growth YoY	17%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

SEC Filings

Direct access to Actavia Life Sciences, Inc. (RASP) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Mar 31
2023
- 10-Q Dec 31
- 10-K Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-Q Dec 31
- 10-K Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Actavia Life Sciences, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Actavia Life Sciences, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Actavia Life Sciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Actavia Life Sciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Actavia Life Sciences, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	06/2015	06/2016	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	TTM
Net Margins	-	-	-	-	-	-	-	-	-
ROA	-	-24K%	-78%	-19%	-16K%	-1%	165%	-4K%	-710%
ROE	-	86%	-131%	-37%	200%	29%	41%	227%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	06/2015	06/2016	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	TTM
Debt over FCF	-	-	-0.05	-	-	-	-	-	-
Debt over Equity	-	-	0.04	0.1	-0.13	-0.11	-0.01	-0	-0.02
Growth Stability	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.02)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	06/2015	06/2016	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	-
Earnings YoY growth	-	271%	6K%	-77%	471%	-85%	-13%	547%	-
Equity YoY growth	-	554%	-4K%	-18%	-205%	-0%	-37%	16%	-0%
FCF YoY growth	-	-	-	-	-	-	-	-	-